A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid

NCT06221072 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

1360

Enrollment

INDUSTRY

Sponsor class

Conditions

Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors

Interventions

DRUG: JMT103
DRUG: zoledronic acid

Sponsor

Shanghai JMT-Bio Inc.